Immunovant, Inc.IMVTNASDAQ
LOADING
|||
Cash Flow Under Pressure
Trending lower, below historical average, strong compound growth.
Left:
||||
Operating cash flow minus capital expenditures
Latest
$-376.63M
↓ 155% below average
Average (7y)
$-147.47M
Historical baseline
Range
High:$-28.60M
Low:$-376.63M
CAGR
+16.6%
Consistent expansion
| Period | Value | Change |
|---|---|---|
| 2025 | $-376.63M | -75.5% |
| 2024 | $-214.59M | -13.9% |
| 2023 | $-188.39M | -77.1% |
| 2022 | $-106.37M | -27.3% |
| 2021 | $-83.54M | -56.5% |
| 2020 | $-53.39M | -86.7% |
| 2019 | $-28.60M | +77.7% |
| 2018 | $-128.30M | - |